FATE director granted 87,900 stock options

FATE Therapeutics director Karin Jooss received a routine stock option grant as part of non-employee director compensation.

Rhea-AI Filing Summary

FATE Therapeutics director Karin Jooss received a routine stock option grant as part of non-employee director compensation. She was awarded options for 87,900 shares of common stock at an exercise price of $2.06 per share, expiring in 2036. The options vest on the earlier of June 12, 2027 or the company’s 2027 annual stockholder meeting, subject to continued board service, and represent compensation rather than an open-market purchase or sale.

Insights

Insider compensation and governance analyst

Director received a standard option grant as equity compensation, with no open-market trading.

The reporting person, director Karin Jooss, was granted options covering 87,900 shares of FATE Therapeutics common stock at an exercise price of $2.06 per share. The transaction is coded as an acquisition (A) and reflects a grant or award, not a market buy.

The footnotes state the grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards on the date of the annual stockholder meeting. This indicates a scheduled, policy-based grant rather than a discretionary timing decision.

The options expire on June 12, 2036 and vest on the earlier of June 12, 2027 or the 2027 annual meeting, contingent on continued board service. Following the grant, Jooss holds options for 87,900 shares, underscoring that this filing reflects routine board compensation with neutral investment signal.

Insider Trade Summary

Grant/Award: 87,900 shares

Grant/Award 1 txn

Insider Jooss Karin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	87,900	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 87,900 contracts (Direct)

Footnotes (2)

1. F1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
2. F2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Key Figures

Option grant size: 87,900 shares Exercise price: $2.06 per share Expiration date: June 12, 2036 +3 more

6 metrics

Option grant size 87,900 shares Stock Option (Right to Buy) grant to director

Exercise price $2.06 per share Conversion or exercise price of granted options

Expiration date June 12, 2036 Option expiration for director grant

Total options after grant 87,900 options Total derivative securities following transaction

Vesting date trigger June 12, 2027 Earlier of June 12, 2027 or 2027 annual meeting

Grant price at award $0.00 per option Compensation grant, not purchased in market

Key Terms

Stock Option (Right to Buy), Amended and Restated Non-Employee Director Compensation Policy, Annual Meeting of Stockholders, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Amended and Restated Non-Employee Director Compensation Policy financial

"grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy"

Annual Meeting of Stockholders financial

"annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders"

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karin Jooss report in this Form 4 for FATE Therapeutics (FATE)?

Karin Jooss reported receiving a grant of stock options for 87,900 shares of FATE Therapeutics common stock. The options were awarded as non-employee director compensation, not through open-market trading, and therefore represent standard equity-based pay rather than a buy or sell decision.

What are the key terms of Karin Jooss’s FATE stock option grant?

The grant covers 87,900 shares of FATE Therapeutics common stock with an exercise price of $2.06 per share. The options expire on June 12, 2036, providing a long-dated incentive aligned with the company’s performance over time.

When do Karin Jooss’s FATE Therapeutics options vest?

These options vest and become exercisable on the earlier of June 12, 2027 or the date of FATE Therapeutics’ 2027 Annual Meeting of Stockholders. Vesting is contingent on her continued service on the company’s board of directors through that date.

Is Karin Jooss’s Form 4 transaction a market purchase or sale of FATE stock?

No. The Form 4 shows a grant of stock options as compensation, coded as an acquisition (A), with a price of $0.00 per option at grant. It does not reflect any open-market purchase or sale of FATE common shares.

What policy governs this FATE director stock option grant to Karin Jooss?

The option grant was made under FATE Therapeutics’ Amended and Restated Non-Employee Director Compensation Policy. This policy provides for annual equity grants to non-employee directors on the date of the company’s Annual Meeting of Stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jooss Karin

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.06	06/12/2026		A(1)		87,900		(2)	06/12/2036	Common Stock	87,900	$0	87,900	D

Explanation of Responses:

1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

	/s/ Cindy Tahl, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)